The National Institute for Health and Clinical Excellence has recommended Ozurdex for the treatment of macular oedema due to central retinal vein occlusion (CRVO) according to manufacturer Allergan.
The pharmaceutical company added that NICE had also recommended the drug, which is applied as an intravitreal implant, for the treatment of branch retinal vein occlusion (BRVO) where laser photocoagulation is neither beneficial nor appropriate. Allergan stated that up to 25,000 patients in the UK every year suffer from macular oedema associated with RVO and may be suitable for treatment with Ozurdex.
The drug is a biodegradable intravitreal implant containing dexamethasone, a corticosteroid, administered via a single use applicator. Dexamethasone acts locally to control oedema, reduce inflammation around the occlusion and improve vision. Allergan reported that a single injection had been shown to offer benefits for up to six months.
Register now to continue reading
Thank you for visiting Optician Online. Register now to access up to 10 news and opinion articles a month.
Register
Already have an account? Sign in here